Haut Lévêque Cardiology Hospital
Pessac, France, 33604
NCT Number: NCT07299721
Congenital heart defects affect 1 in 100 births in France, with rising prevalence due to better care. Despite improved survival, 40% of children post-surgery face neurological impairments, and some of them show brain lesions. Causes include heart defects, genetic syndromes, and surgeries. Some heart defects and support systems increase cerebral risks. Monitoring cerebral perfusion is difficult to assess but emerging ultrafast ultrasound offers real-time, non-invasive blood flow insights.
Trial opening soon.
Get Notified0 year–2 year
All sexes
Observational
Pessac, France, 33604
Congenital heart defects affect 1 in 100 live births in France. While incidence remains stable, prevalence is rising due to improved medical care, with cases expected to double by 2050. Despite increased survival, neurological comorbidities remain a major concern, with 40% of patients undergoing childhood cardiac surgery experiencing impairments and 73% presenting MRI-detectable brain lesions postoperatively. These injuries result from congenital heart defects, haemodynamic disturbances, genetic syndromes, and neonatal surgeries with extracorporeal circulation.
Some heart defects, such as systemic-to-pulmonary shunts and cyanotic heart diseases, impair cerebral perfusion, increasing the risk of hypoxia and stroke. Mechanical circulatory support systems (e.g. ECMO, cardiopulmonary bypass) also contribute to cerebral risks due to hypoperfusion and clotting complications.
Cerebral autoregulation helps maintain stable perfusion despite blood pressure variations. However, bedside cerebral perfusion monitoring remains challenging leading to reliance on indirect methods like near-infrared spectroscopy (NIRS) and transcranial Doppler (TCD), both with limitations. Ultrafast ultrasound (UFUS) is an emerging non-invasive technique that enables real-time quantification of cerebral blood flow, offering new insights into neonatal cerebral haemodynamics.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ultrafast ultrasound imaging(UFUS), ultrasound images at a very high rate, using a Verasonics system (ultrasound open platform).
Time frame: at baseline
Depending on stage of medico-surgical treatment
Time frame: at baseline
Depending on hemodynamic or ventilatory situation, and exposure to vasoactive or neuroactive drugs.
Time frame: at baseline
Time frame: at baseline
Time frame: at baseline
Time frame: at baseline
Time frame: at baseline
Time frame: at baseline
Time frame: at baseline
Time frame: at baseline
Time frame: at baseline
Time frame: at baseline
Time frame: at baseline
Time frame: at baseline
Time frame: at baseline
Contact information is provided by the study sponsor or research team.
University Hospital, Bordeaux
Other
Brain Ultrafast Ultrasound Imaging: Application in Pediatric Cardiology: Brain Ultrafast
Acronym: Brain Ultrafas
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07115589
CHD - Congenital Heart Disease, Cardiovascular Abnormalities
Pessac, France
View Trial DetailsNCT06998290
CHD - Congenital Heart Disease, Cardiovascular Abnormalities
Montpellier, France
View Trial DetailsNCT06958120
Agnosia, CHD - Congenital Heart Disease
Cairo, Egypt
View Trial DetailsNCT07686341
CHD - Congenital Heart Disease, Cardiovascular Abnormalities
Memphis, Tennessee, United States
View Trial Details